Coiled Therapeutics Plc COIL
LSE · United Kingdom · Health Technology
GBp 7.500.00 (0.00%)
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) said it expects to report the first safety data from a new version of its cancer drug AO-252 before the end of 2026. The developer of treatments for cancers driven by specific genetic changes plans to dose up to 30 patients with the new formulation...
Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) executive chairman Dr Sotirios Stergiopoulos spoke with Proactive's Stephen Gunnion about progress with the company's new drug formulation of AO-252, including the enrolment of the first six patients across the 120mg twice-daily and 160mg once-daily cohorts. Stergiopoulos explained that the initial cohorts are designed to provide important exposure data for the new formulation. The previous version had encountered solubility limitations as doses increased, restricting how much drug reached the patient, and Coiled is now looking to establish whether t
Shore Capital has welcomed the latest step forward in Coiled Therapeutics' (AIM:COIL, OTCQB:COTXF) cancer drug trial, reiterating its support for the AIM-listed group. The broker was responding to Monday's news that Coiled had enrolled six patients across two dose groups testing a...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.